Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
15.50
+0.04 (0.26%)
Dec 20, 2024, 4:00 PM EST - Market closed
Arcus Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 263 | 117 | 112 | 383 | 78 | 15 | Upgrade
|
| Revenue Growth (YoY) | 119.17% | 4.46% | -70.76% | 391.03% | 420.00% | 79.58% | Upgrade
|
| Cost of Revenue | 440 | 340 | 288 | 257 | 159 | 78.48 | Upgrade
|
| Gross Profit | -177 | -223 | -176 | 126 | -81 | -63.48 | Upgrade
|
| Selling, General & Admin | 121 | 117 | 104 | 72 | 43 | 25.23 | Upgrade
|
| Operating Expenses | 121 | 117 | 104 | 72 | 43 | 25.23 | Upgrade
|
| Operating Income | -298 | -340 | -280 | 54 | -124 | -88.71 | Upgrade
|
| Interest Expense | -2 | -2 | -2 | - | - | - | Upgrade
|
| Interest & Investment Income | 51 | 41 | 16 | 1 | 1 | 5.2 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | - | -1.2 | Upgrade
|
| EBT Excluding Unusual Items | -249 | -301 | -266 | 55 | -123 | -84.71 | Upgrade
|
| Pretax Income | -269 | -301 | -266 | 55 | -123 | -84.71 | Upgrade
|
| Income Tax Expense | 1 | 6 | 1 | 2 | - | - | Upgrade
|
| Net Income | -270 | -307 | -267 | 53 | -123 | -84.71 | Upgrade
|
| Net Income to Common | -270 | -307 | -267 | 53 | -123 | -84.71 | Upgrade
|
| Shares Outstanding (Basic) | 86 | 74 | 72 | 69 | 55 | 44 | Upgrade
|
| Shares Outstanding (Diluted) | 86 | 74 | 72 | 74 | 55 | 44 | Upgrade
|
| Shares Change (YoY) | 17.25% | 2.78% | -2.70% | 35.04% | 25.04% | 26.60% | Upgrade
|
| EPS (Basic) | -3.14 | -4.15 | -3.71 | 0.76 | -2.24 | -1.93 | Upgrade
|
| EPS (Diluted) | -3.14 | -4.15 | -3.71 | 0.71 | -2.24 | -1.93 | Upgrade
|
| Free Cash Flow | -169 | -330 | 432 | -282 | 108 | -75.39 | Upgrade
|
| Free Cash Flow Per Share | -1.97 | -4.46 | 6.00 | -3.81 | 1.97 | -1.72 | Upgrade
|
| Gross Margin | -67.30% | -190.60% | -157.14% | 32.90% | -103.85% | - | Upgrade
|
| Operating Margin | -113.31% | -290.60% | -250.00% | 14.10% | -158.97% | -591.39% | Upgrade
|
| Profit Margin | -102.66% | -262.39% | -238.39% | 13.84% | -157.69% | -564.73% | Upgrade
|
| Free Cash Flow Margin | -64.26% | -282.05% | 385.71% | -73.63% | 138.46% | -502.58% | Upgrade
|
| EBITDA | -288 | -332 | -274 | 58 | -121 | -85.13 | Upgrade
|
| EBITDA Margin | -109.51% | -283.76% | -244.64% | 15.14% | -155.13% | - | Upgrade
|
| D&A For EBITDA | 10 | 8 | 6 | 4 | 3 | 3.58 | Upgrade
|
| EBIT | -298 | -340 | -280 | 54 | -124 | -88.71 | Upgrade
|
| EBIT Margin | -113.31% | -290.60% | -250.00% | 14.10% | -158.97% | - | Upgrade
|
| Effective Tax Rate | - | - | - | 3.64% | - | - | Upgrade
|
| Revenue as Reported | 263 | 117 | 112 | 383 | 78 | 15 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.